Interested in patient engagement? Subscribe to the PARADIGM newsletter!


Patient engagement is becoming increasingly important for the pharmaceutical industry, health technology assessment bodies and regulators. PREFER has signed a memorandum of understanding with the PARADIGM project (Patients Active in Research and Dialogues for an Improved Generation of Medicines). We encourage everyone who is interested in patient engagement to sign up to the PARADIGM newsletter!

Like PREFER, PARADIGM is a public-private partnership led by the European Patients’ Forum and EFPIA together. The mission is to provide a framework to enable structured, effective, meaningful, ethical, innovative, and sustainable patient engagement and demonstrate how this engagement is returned for all parties involved. 

Receive news from PARADIGM



The two Innovative Medicines Initiative (IMI) consortia PARADIGM, Patients Active in Research and Dialogues for an Improved Generation of Medicine (co-led by the European Patients’ Forum and the European Federation of Pharmaceutical Industries and Associations) and PREFER, Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (co-led by Uppsala University and Novartis) have established a Memorandum of Understanding aiming to enhance the cooperation and collaboration between the two projects.

Read about our collaboration

Receive news from PREFER

Last modified: 2021-11-10